The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InLabcorp (NYSE: LH) has officially launched the first U.S.-manufactured, FDA-cleared rapid fentanyl urine visual test, marking a significant milestone in clinical diagnostics. Designed specifically for emergency departments and hospitals, the test delivers critical results within just 10 minutes. By detecting norfentanyl, a key metabolite of fentanyl, the tool enables healthcare providers to make rapid and informed patient care decisions during emergencies. This launch addresses the urgent need for fast diagnostic solutions to combat the ongoing fentanyl crisis. Analysts view this move as a strategic boost to Labcorp's market position, following its robust Q4 earnings performance. The introduction of this point-of-care technology underscores the company's commitment to innovation in the healthcare sector.